Phase 3 Multiple Sclerosis Trial, Recruiting (ISRCTN99207647)

Phase 3 Multiple Sclerosis Trial, Recruiting ISRCTN99207647 Sponsor: Queen Mary University of London Condition: Multiple Sclerosis

Printed from Voxsanity (voxsanity.com.au) — ISRCTN99207647 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Multiple Sclerosis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People aged 18 years or older
People who have been diagnosed with Multiple Sclerosis (MS), or who have had a first episode of symptoms that doctors believe may be related to damage to the nervous system
People who are already scheduled to have an MRI scan of their head as part of their care
People who are already on a treatment pathway for MS (meaning a doctor has started or is planning MS-related medication)
People who have access to a smartphone, tablet, or computer

Who may not be able to join:

People with MS who are currently taking part in a separate clinical trial that involves testing an experimental medicine (however, people with MS taking part in a single-arm study — where everyone receives the same treatment with no comparison group — may still be considered eligible, provided the rules of that other study allow it (confirm with trial site))

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 10 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: ISRCTN99207647

Sponsor: Queen Mary University of London

Phase: Phase 3

Status: Recruiting

Condition: Multiple Sclerosis

More information: https://www.isrctn.com/ISRCTN99207647

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People aged 18 years or older
People who have been diagnosed with Multiple Sclerosis (MS), or who have had a first episode of symptoms that doctors believe may be related to damage to the nervous system
People who are already scheduled to have an MRI scan of their head as part of their care
People who are already on a treatment pathway for MS (meaning a doctor has started or is planning MS-related medication)
People who have access to a smartphone, tablet, or computer

Who may not be able to join:

People with MS who are currently taking part in a separate clinical trial that involves testing an experimental medicine (however, people with MS taking part in a single-arm study — where everyone receives the same treatment with no comparison group — may still be considered eligible, provided the rules of that other study allow it (confirm with trial site))

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 10 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

Queen Mary University of London

Registry

ISRCTN registry

Start date

15 April 2025

Est. completion

15 April 2027

Where this trial is recruiting

England 🇬🇧 United Kingdom

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from the ISRCTN registry: 10 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ISRCTN ↗

Source: ISRCTN registry (isrctn.com), data processed 10 July 2026. ISRCTN metadata is CC0; contribution content is CC BY 4.0.